BioSpace News Archive

Blue Earth Diagnostics announced highlights from clinical studies conducted by its collaborators at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8-11, 2024.

Palisade Bio, Inc. announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 12:00 PM ET.

In a strategic move that could reshape the understanding of long COVID and chronic Lyme disease, the Massachusetts Institute of Technology has forged a partnership with Movano Health for its MAESTRO study to harness the medical grade continuous health monitoring capabilities of Movano’s Evie Ring.

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced the publication of a significant research article in the European Society of Medicine Journal. The study investigates the effects of CYP2C9 polymorphisms on the pharmacokinetics (“PK”) of delta-9-tetrahydrocannabinol (“THC”) and its active metabolite in Alzheimer’s disease (“AD”) patients.

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies

DeepQure, a Seoul based medical device company with a novel, extravascular solution for renal denervation, announced initiation of its Early Feasibility Study for the HyperQure™ system following FDA IDE approval.

GC Biopharma and Novel Pharma have announced that the U.S. FDA has granted Fast Track Designation for their jointly developed MPSIIIA treatment, GC1130A.

Moderna, Inc. announced that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial.

PolyPid Ltd. announced that it will host a virtual Key Opinion Leader event on Monday, June 17, 2024, at 10:00 AM ET, to discuss the significant unmet medical need in surgical site infections and provide an update on the Company’s ongoing D-PLEX100 Phase 3 trial.

Nurix Therapeutics, Inc. announced that the company will host a webcast and conference call at 9:00 a.m., ET, on Sunday, June 16, 2024, to discuss data from the ongoing Phase 1 clinical trial of NX-5948 that will be presented in an oral session at the European Hematology Association Congress in Madrid, Spain.